The Vaccines business represents 14% of the overall turnover of GSK.
Our Vaccines business is one of the largest in the world, developing, producing and distributing over 2.5 million vaccines every day to people across 170 countries.
GSK Vaccines have been helping protect people from serious disease since the 1950s, when we introduced our first polio vaccine. Our vaccines help protect people from many other illnesses, including pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough and influenza. Our pipeline of potential new vaccines covers many of the diseases still having a serious impact around the world, including malaria, HIV, TB and Ebola.
Our acquisition of Novartis Vaccines (excluding influenza vaccines) in early 2015 significantly expanded the number of vaccines we produce (now around 40), as well as the number of new vaccines we have in development (17), giving us the broadest portfolio of any vaccines company in the world.
GSK Vaccines, located in Rixensart, Wavre and Gembloux, is the worldwide centre for the research, development and manufacturing activities of the vaccines of GSK. Almost one-fourth of the more than 8,000 people who work at GSK Vaccines in Belgium specialise in the discovery of new vaccines and the development of combination products for the prevention of infections that cause serious medical problems in the world.
We believe that the protection from life-threatening diseases provides opportunities for greater health not just for individuals, but also for the communities in which they live.
For the least developed countries, we work closely with GAVI and UNICEF. These organizations are able to purchase large volumes of vaccines for the world’s poorest children at our lowest prices. Just over 80% of our vaccines go to the developing world.
Research and collaboration
Scientific advances are central to our ability to innovate, and we continue to invest in de the science to discover and develop new vaccines, both to protect against diseases where vaccines are not yet available and to improve on those vaccines that already exist. This research includes our efforts to find new vaccines against malaria, HIV and tuberculosis. Find out more about how we are partnering and collaborating in order to drive research.
BE/COM/0007/15(2) Oct 2017